Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05529849 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects
A Phase 1 study, sponsored by Endevica Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT05529849 is a Phase 1 study that has completed, run by Endevica Bio. The registered enrollment target is 76 participants.
The verdict
NCT05529849, a Phase 1 study, has completed, sponsored by Endevica Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia. Cachexia occurs in many cancers, usually at the advanced stages of disease.
Interventions
- DRUG Placebo
- DRUG TCMCB07
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2023-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05529849
The ClinicalTrials.gov registry entry for NCT05529849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endevica Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05529849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05529849 about?
NCT05529849 is a clinical study titled "A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects". This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia. Cachexia occurs in many cancers, usually at the advanced stages of disease.
What is the current status of trial NCT05529849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2022-07-12. Estimated completion is 2023-02-20.
What interventions are being tested in trial NCT05529849?
The interventions under investigation include: Placebo (DRUG), TCMCB07 (DRUG).
Who is sponsoring clinical trial NCT05529849?
This trial is sponsored by Endevica Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.